GlaxoSmithKline (GSK) and Innoviva have filed an application for their respiratory drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) in the US seeking its use for the treatment of asthma in adults.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,